Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) and Surface
Oncology, Inc. (Surface, Nasdaq: SURF) today announced that the
companies have entered into a definitive merger agreement providing
that, at the closing, Coherus will acquire Surface Oncology, a
clinical-stage immuno-oncology (I-O) company developing
next-generation immunotherapies that target the tumor
microenvironment. The Surface acquisition adds two differentiated
clinical stage assets to Coherus’ novel I-O pipeline: SRF388, a
novel IL-27-targeted antibody currently being evaluated in Phase 2
clinical trials in lung cancer and liver cancer, and SFR114, a
CCR8-targeted antibody currently in a Phase 1/2 study as a
monotherapy in patients with advanced solid tumors.
The transaction was unanimously approved by the
boards of directors of both companies and is expected to close in
the third quarter of 2023.
“This transaction is well-timed, as it coincides
with the accelerating growth of our biosimilar revenues driven by
the launch of CIMERLI® and near-term launch of YUSIMRY®. With the
agreement to acquire Surface and the expected near-term approval of
toripalimab, Coherus is positioned to become one of the very few
I-O companies with demonstrated commercial expertise, significant
product revenues, and unique, competitively positioned R&D
programs addressing critical unmet medical needs,” said Denny
Lanfear, Chairman and Chief Executive Officer of Coherus.
“Toripalimab has recently demonstrated potentially
practice-changing overall survival data in nasopharyngeal
carcinoma, and its differentiated mechanism of action defines it as
a next-generation PD-1. Existing marketed PD-1’s transformed the
treatment of cancer over the past decade but are effective in only
a minority of patients. Additional overall survival gains must come
from novel combinations that more broadly target the cancer
immunity cycle. The addition of Surface’s IL-27 and CCR8 antibodies
expands our next-generation I-O pipeline beyond checkpoint
inhibition to agents targeting immune-suppressive mechanisms of the
tumor microenvironment.”
Commenting on the merger, Rob Ross, MD,
President and Chief Executive Officer, Surface said, "This
combination presents a rare opportunity for two complementary
organizations to join together and forge something that is greater
than the sum of its parts. By augmenting Coherus’ existing
capabilities and infrastructure with Surface’s innovative pipeline
and deep I-O expertise, Coherus is well positioned to develop
important I-O medicines for patients which deliver real value for
the shareholders of both companies.”
Regarding the SRF388 data, Dr. Ross added,
“While still early, the new hepatocellular carcinoma (HCC) data are
encouraging and suggest that when administered in triplet
combination with checkpoint and VEGF inhibitors, SRF388 holds
exciting potential to improve the treatment paradigm for liver
cancer. Based on the growing body of data in HCC, non-small-cell
lung cancer (NSCLC) and renal cell carcinoma (RCC), SRF388 would be
a compelling agent to study in combination with toripalimab in many
highly prevalent tumor types.”
Benefits of the Transaction
Strengthens Coherus’ pipeline with
global rights to innovative, competitively positioned,
clinical-stage I-O assets
- SRF388, the only
IL-27 targeted antibody in clinical development worldwide, has
demonstrated monotherapy activity in multiple tumor types and is
currently being evaluated in Phase 2 clinical trials in lung cancer
and liver cancer as monotherapy and in combination with checkpoint
inhibitors.
- SRF114, a high
affinity, fully human IgG1 antibody demonstrated to bind
exclusively to CCR8, has established proof of mechanism with
pharmacodynamic activity observed in the ongoing Phase 1
trial.
- SRF388 and
SRF114 have potential as monotherapy and as combination treatments
with other I-O agents, including Coherus’ toripalimab.
Expands Coherus’ I-O franchise to the
treatment of tumor types with significant unmet needs
- Coherus plans to
launch toripalimab directly upon approval by the United States Food
and Drug Administration (FDA) for nasopharyngeal carcinoma.
- Coherus plans to
evaluate SRF388 and SRF114 as monotherapies and in combination with
toripalimab for lung cancer, head and neck cancer, and certain
other tumor types.
- Novel I-O
clinical development will extend Coherus’ reach in oncology and
expand physician experience with toripalimab. Combinations of
toripalimab with SRF388 or SRF114 could yield net sales from
multiple Coherus proprietary I-O agents.
Positive financial impact
- $20 - $25
million in Surface net cash projected at closing will strengthen
Coherus’ balance sheet and fund ongoing SRF388 and SRF114 clinical
trials through year-end 2024, beyond significant value inflection
points in 2023 and 2024.
- Pipeline
prioritization enabled by the acquisition will focus clinical
development activities on competitively positioned I-O programs and
reduce budgeted R&D spending by at least $50 million through
2025.
- Potential
out-licensing of ex-US rights to SRF388 and SRF114 could raise
significant non-dilutive capital in 2024 and 2025.
Transaction Details
Under the terms of the agreement, Coherus will
issue shares of its common stock at a price of $5.2831 per share to
acquire all outstanding shares of Surface stock for a total value
equal to the sum of $40 million plus Surface’s net cash at closing
of the transaction (currently expected to be between $20 and $25
million). Surface shareholders will also receive CVRs for 70% of
milestone and royalty-based value of existing programs with
Novartis AG (NZV930) and GSK plc (GSK4381562), as well as CVRs for
25% of upfront payments made pursuant to potential ex-US licensing
agreements for SRF114 and 50% of upfront payments made pursuant to
potential ex-US licensing agreements for SRF388, subject to certain
deductions as set forth in the contingent value rights agreement.
Amounts under these CVRs are payable for a period of ten years
following the closing of this transaction.
The transaction was unanimously approved by the
boards of directors of both companies and is expected to close in
the third quarter of 2023. The closing of the transaction is
subject to certain conditions, including Surface shareholder
approval; the availability at closing of at least $19.6 million of
Surface cash net of short-term and long-term liabilities,
transaction expenses, and other obligations; and other customary
conditions. In conjunction with the transaction announcement,
Surface is implementing a workforce reduction of approximately 50%
of its employees.
Truist Securities is acting as financial advisor
and Arnold & Porter Kaye Scholer LLP and Latham & Watkins
LLP are acting as legal advisors to Coherus. Wedbush Securities
Inc. is acting as exclusive strategic financial advisor and Goodwin
Procter LLP is acting as legal advisor to Surface.
Coherus financial guidance
For Q2 2023, Coherus expects to report at least
$48 - 53 million of net product revenue from sales of UDENYCA® and
CIMERLI®. For the fiscal year 2023, Coherus continues to project
net revenues in excess of $275 million, including at least $100
million from net sales of CIMERLI®, with the balance comprising net
sales of UDENYCA®, YUSIMRY™ and toripalimab. Additionally, Coherus
affirms prior guidance for full year 2023 combined R&D and
SG&A expenses in the range of $315 to $335 million, including
approximately $50 million of stock-based compensation expense and
excluding the Surface Oncology acquisition cost as well as any
potential collaboration upfront payments to Klinge Pharma for the
in-license of its Eylea® biosimilar program or milestone payments
to Junshi Biosciences due upon U.S. approval of toripalimab.
Surface program updates
SRF388, a novel antibody targeting
IL-27
- In the Phase 2
study evaluating SRF388 as a monotherapy in NSCLC, two confirmed
partial responses were observed as of the data cut-off (April 14,
2023) in PD-L1 negative or low patients with squamous NSCLC, as
well as one confirmed report of durable disease stabilization in a
patient with adenocarcinoma. All 3 of these patients were
previously treated with PD-(L)1 antibodies. The overall response
rate (ORR) in the subset of patients with squamous NSCLC (n=2/6)
was 33% in this data cut.
- Surface has
fully enrolled the lead-in stage of the Phase 2 trial investigating
SRF388 in combination with atezolizumab and bevacizumab for
patients with first-line advanced hepatocellular carcinoma (n=30).
In an early data cut (April 2023) with an average of 15 weeks of
follow-up and only approximately half of patients with more than
one post-treatment imaging assessment, SRF388 in combination with
atezolizumab and bevacizumab demonstrated a 27% ORR (n=7/26) with a
65% disease control rate in response-evaluable patients.
Additional follow-up data are expected by the end of the
year.
- SRF388 has
demonstrated an acceptable safety profile in both studies to date,
and there were no concerning safety signals observed in either
trial as monotherapy or in combination with other agents including
checkpoint inhibitors.
SRF114, a highly selective,
competitively positioned antibody targeting CCR8
- The Phase 1
trial of SRF114 in patients with advanced solid tumors is currently
enrolling in monotherapy dose escalation (n=6). Early evidence of
biological effect has been seen with regulatory T cell depletion in
peripheral blood CCR8+ Treg cells following treatment with SRF114,
with no effect observed on non-CCR8+ Treg cells. No concerning
safety signals were observed to date and dose escalation
continues.
Near-term projected I-O
catalysts
- Q3 2023: FDA approval decision on
toripalimab
- Q4 2023: toripalimab mechanism of
action/differentiation as a next generation PD-1 presentation;
SRF388 NSCLC data presentation; ILT4 investigational new drug
filing
- Q1 2024: SRF388 HCC combination
data presentation
- Q2 2024: ILT4 preclinical data
presentation; SRF114 Phase 1 data
Conference Call and Webcast
Information
Coherus and Surface Oncology management will
host a conference call to review details of the transaction
beginning at 8:30 a.m. Eastern Daylight Time/5:30 a.m. Pacific
Daylight Time, June 16, 2023.
The press release and live webcast of the
conference call can be accessed through a link that is posted on
Investors section of the Coherus website:
https://investors.coherus.com/ and Investors section of the Surface
Oncology website: https://investors.surfaceoncology.com/.
Webcast Link:
https://edge.media-server.com/mmc/p/zfig6oyn
To access the live conference call, please
pre-register through the following link:
https://register.vevent.com/register/BId34739a2380b43eb83e35ac0ed20eb29
All registrants will receive dial-in information
and a PIN allowing them to access the live call.
The webcast replay will be available on the
Coherus and Surface websites upon completion of the event.
About Surface’s Immuno-oncology
Pipeline
Surface’s immuno-oncology pipeline includes
multiple antibody immunotherapy candidates focused on enhancing the
innate and adaptive immune responses to enable a robust immunologic
response and enhance outcomes for patients with cancer. SRF388 is a
novel anti-IL-27 antibody currently being evaluated in Phase 1/2
clinical trials in lung and liver cancer. SRF114 is a highly
selective, competitively positioned anti-CCR8 antibody currently in
a Phase 1/2 study as a monotherapy in patients with advanced solid
tumors. Surface also has two out-licensed partnership programs to
advance its next-generation cancer therapies.
About Coherus’ Immuno-oncology
Pipeline
Coherus is developing an innovative
immuno-oncology pipeline that will be synergistic with its proven
commercial capabilities in oncology. Through an in-licensing
agreement with Junshi Biosciences, Coherus is developing
toripalimab, an anti-PD-1 antibody, in the United States and
Canada. A biologics license application for toripalimab for the
treatment of nasopharyngeal carcinoma (NPC) is under review by the
FDA. Toripalimab is approved in China for the second-line treatment
of melanoma, urothelial cancer, and nasopharyngeal carcinoma.
Coherus’ earlier-stage immuno-oncology pipeline
targets immune-suppressive mechanisms in the tumor
microenvironment, including CHS-006, a TIGIT-targeted antibody,
being evaluated in a Phase 1/2 clinical trial in combination with
toripalimab in patients with advanced solid tumors, and CHS-1000, a
preclinical program targeting the novel pathway ILT4.
About Coherus BioSciences
Coherus is a commercial-stage biopharmaceutical
company focused on the research, development and commercialization
of innovative immunotherapies to treat cancer. Coherus’ strategy is
to build a leading immuno-oncology franchise funded with cash
generated through net sales of its diversified portfolio of
FDA-approved therapeutics.
In 2021, Coherus in-licensed toripalimab, an
anti-PD-1 antibody, in the United States and Canada. The Biologics
License Application for toripalimab in combination with
chemotherapy as treatment for recurrent or metastatic
nasopharyngeal carcinoma is currently under review by the FDA.
Coherus markets UDENYCA® (pegfilgrastim-cbqv), a
biosimilar of Neulasta®, and CIMERLI®(ranibizumab-eqrn), a
biosimilar of Lucentis®, in the U.S., and expects to launch the
FDA-approved Humira® biosimilar YUSIMRY™ (adalimumab-aqvh) in the
U.S. in July 2023.
About Surface Oncology
Surface Oncology is an immuno-oncology company
developing next-generation antibody therapies focused on the tumor
microenvironment. Its pipeline includes two wholly-owned programs:
SRF388, a Phase 2 program that targets IL-27, and SRF114, a Phase 1
program, which selectively depletes regulatory T cells in the tumor
microenvironment via targeting CCR8. In addition, Surface has two
partnerships with major pharmaceutical companies: a collaboration
with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration
with GlaxoSmithKline targeting PVRIG (GSK4381562, formerly SRF813;
Phase 1). Surface’s novel investigational cancer immunotherapies
are designed to achieve a clinically meaningful and sustained
anti-tumor response and may be used alone or in combination with
other therapies.
Forward-Looking StatementsThis
communication relates to the proposed transaction pursuant to the
terms of the Agreement and Plan of Merger, dated June 15, 2023, by
and among Coherus, Crimson Merger Sub I, Inc. (Merger Sub I),
Crimson Merger Sub II, LLC (Merger Sub II), and Surface. This
communication includes express or implied forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended (the Exchange Act), about the proposed
transaction between Coherus and Surface and the operations of the
combined company that involve risks and uncertainties relating to
future events and the future performance of Coherus and Surface.
Actual events or results may differ materially from these
forward-looking statements. Words such as “will,” “could,” “would,”
“should,” “expect,” “plan,” “anticipate,” “intend,” “believe,”
“estimate,” “predict,” “project,” “potential,” “continue,”
“future,” “opportunity,” “will likely result,” “target,” variations
of such words, and similar expressions or negatives of these words
are intended to identify such forward-looking statements, although
not all forward-looking statements contain these identifying words.
Examples of such forward-looking statements include, but are not
limited to, express or implied statements regarding: the business
combination and related matters, including, but not limited to,
satisfaction of closing conditions to the proposed transaction,
prospective performance and opportunities with respect to Coherus,
Surface or the combined company, post-closing operations and the
outlook for the companies’ businesses; prospective developments or
results in the pipelines of Coherus, Surface or the combined
company and expansion of Coherus’ I-O franchise; the prospects for
approval of toripalimab; Coherus’, Surface’s or the combined
company’s targets, plans, objectives or goals for future
operations, including those related to Coherus’ and Surface’s
product candidates, research and development, product candidate
introductions and product candidate approvals as well as
cooperation in relation thereto; projections of or targets for
revenues, costs and other financial measures; future economic
performance; and the assumptions underlying or relating to such
statements. These statements are based on Coherus’ and Surface’s
current plans, estimates and projections. By their very nature,
forward-looking statements involve inherent risks and
uncertainties, both general and specific. A number of important
factors, including those described in this communication, could
cause actual results to differ materially from those contemplated
in any forward-looking statements. Factors that may affect future
results and may cause these forward-looking statements to be
inaccurate include, without limitation: uncertainties as to the
timing for completion of the proposed transaction; uncertainties as
to Surface’s ability to obtain the approval of Surface’s
shareholders required to consummate the proposed transaction; the
possibility that competing offers will be made by third parties;
the occurrence of events that may give rise to a right of one or
both of Coherus and Surface to terminate the merger agreement; the
possibility that various closing conditions for the proposed
transaction may not be satisfied or waived on a timely basis or at
all, including the possibility that a governmental entity or
regulatory authority may prohibit, delay, or refuse to grant
approval, if required, for the consummation of the proposed
transaction (or only grant approval subject to adverse conditions
or limitations); the difficulty of predicting the timing or outcome
of consents or regulatory approvals or actions, if any; the
possibility that the proposed transaction may not be completed in
the time frame expected by Coherus and Surface, or at all; the risk
that Coherus and Surface may not realize the anticipated benefits
of the proposed transaction in the time frame expected, or at all;
the effects of the proposed transaction on relationships with
Coherus’ or Surface’s employees, business or collaboration partners
or governmental entities; the ability to retain and hire key
personnel; potential adverse reactions or changes to business
relationships resulting from the announcement or completion of the
proposed transaction; significant or unexpected costs, charges or
expenses resulting from the proposed transaction; the potential
impact of unforeseen liabilities, future capital expenditures,
revenues, costs, expenses, earnings, synergies, economic
performance, indebtedness, financial condition and losses on the
future prospects, business and management strategies for the
management, expansion and growth of the combined business after the
consummation of the proposed transaction; potential negative
effects related to this announcement or the consummation of the
proposed transaction on the market price of Coherus’ or Surface’s
common stock and/or Coherus’ or Surface’s operating or financial
results; the difficulty of predicting the timing or outcome of
regulatory approvals or actions; the risks that holders of the CVRs
will not receive payments in respect of the CVRs; uncertainties as
to the long-term value of Coherus’ common stock, including the
dilution caused by Coherus’ issuance of additional shares of common
stock in connection with the proposed transaction; unknown
liabilities related to Coherus or Surface; the nature, cost and
outcome of any litigation and other legal proceedings involving
Coherus, Surface or their respective directors, including any legal
proceedings related to the proposed transaction; risks related to
global as well as local political and economic conditions,
including interest rate and currency exchange rate fluctuations;
potential delays or failures related to research and/or development
of Coherus’ or Surface’s programs or product candidates; risks
related to any loss of Coherus’ or Surface’s patents or other
intellectual property rights; any interruptions of the supply chain
for raw materials or manufacturing for Coherus or Surface’s product
candidates, the nature, timing, cost and possible success and
therapeutic applications of product candidates being developed by
Coherus, Surface and/or their respective collaborators or
licensees; the extent to which the results from the research and
development programs conducted by Coherus, Surface, and/or their
respective collaborators or licensees may be replicated in other
studies and/or lead to advancement of product candidates to
clinical trials, therapeutic applications, or regulatory approval;
uncertainty of the utilization, market acceptance, and commercial
success of Coherus or Surface’s product candidates, and the impact
of studies (whether conducted by Coherus, Surface or others and
whether mandated or voluntary) on any of the foregoing; unexpected
breaches or terminations with respect to Coherus’ or Surface’s
material contracts or arrangements; risks related to competition
for Coherus’ or Surface’s product candidates; Coherus’ or Surface’s
ability to successfully develop or commercialize Coherus’ or
Surface’s product candidates; Coherus’, Surface’s, and their
collaborators’ abilities to continue to conduct current and future
developmental, preclinical and clinical programs; potential
exposure to legal proceedings and investigations; risks related to
changes in governmental laws and related interpretation thereof,
including on reimbursement, intellectual property protection and
regulatory controls on testing, approval, manufacturing,
development or commercialization of any of Coherus’ or Surface’s
product candidates; unexpected increases in costs and expenses with
respect to the potential transaction or Coherus’ or Surface’s
business or operations; and risks and uncertainties related to
epidemics, pandemics or other public health crises and their impact
on Coherus’ and Surface’s respective businesses, operations, supply
chain, patient enrollment and retention, preclinical and clinical
trials, strategy, goals and anticipated milestones. While the
foregoing list of factors presented here is considered
representative, no list should be considered to be a complete
statement of all potential risks and uncertainties. There can be no
assurance that the proposed transaction or any other transaction
described above will in fact be consummated in the manner described
or at all. A more complete description of these and other material
risks can be found in Coherus’ and Surface’s respective filings
with the SEC, including each of their Annual Reports on Form 10-K
for the year ended December 31, 2022, subsequent Quarterly Reports
on Form 10-Q and other documents that may be filed from time to
time with the SEC, as well as the Registration Statement on Form
S-4 which includes the proxy statement of Surface that also
constitutes the prospectus of Coherus, which proxy
statement/prospectus will be mailed or otherwise disseminated to
Surface’s stockholders when it becomes available. Coherus and
Surface also plan to file other relevant documents with the SEC
regarding the proposed transaction. Any forward-looking statements
speak only as of the date of this communication and are made based
on the current beliefs and judgments of Coherus’ and Surface’s
management, and the reader is cautioned not to rely on any
forward-looking statements made by Coherus or Surface. Unless
required by law, neither Coherus nor Surface is under no duty and
undertakes no obligation to update or revise any forward-looking
statement after the distribution of this document, including
without limitation any financial projection or guidance, whether as
a result of new information, future events or otherwise.
No Offer or SolicitationThis
communication is not intended to and shall not constitute an offer
to subscribe for, buy or sell or the solicitation of an offer to
subscribe for, buy or sell any securities, or a solicitation of any
vote or approval, nor shall there be any sale of, or offer to sell
or buy, securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such jurisdiction.
This communication is for informational purposes only. No offering
of securities shall be made, except by means of a prospectus
meeting the requirements of Section 10 of the U.S. Securities Act
of 1933, as amended, and otherwise in accordance with applicable
law.
Additional Information and Where to Find
ItIn connection with the proposed transaction, Coherus and
Surface expect to file with the SEC a Registration Statement on
Form S-4. The Registration Statement on Form S-4 will include a
document that serves as a prospectus of Coherus and a proxy
statement/prospectus of Surface, and each party may also file other
documents regarding the proposed transaction with the SEC.
INVESTORS AND SECURITY HOLDERS ARE URGED TO READ CAREFULLY THE
REGISTRATION STATEMENT ON FORM S-4, PROXY STATEMENT/PROSPECTUS AND
OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC, AS WELL
AS ANY AMENDMENTS OR SUPPLEMENTS THERETO AND ANY DOCUMENTS
INCORPORATED BY REFERENCE THEREIN, IN THEIR ENTIRETY IF AND WHEN
THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN
IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION, RELATED
MATTERS AND THE PARTIES TO THE PROPOSED TRANSACTION.
You may obtain a free copy of the Registration
Statement on Form S-4, proxy statement/prospectus and other
relevant documents (if and when they become available) that are or
will be filed with the SEC for free at the SEC’s website at
www.sec.gov. Copies of the documents filed with the SEC by Surface
will be available free of charge on Surface’s website at
https://investors.surfaceoncology.com/financial-information/sec-filings
or by contacting Surface’s Investor Relations Department at
IR@surfaceoncology.com. Copies of the documents filed with the SEC
by Coherus will be available free of charge on Coherus’ website at
https://investors.coherus.com/financial-information/sec-filings or
by contacting Coherus’ Investor Relations Department at
IR@coherus.com.
Participants in the
SolicitationCoherus, Surface and certain of their
respective directors and executive officers and other members of
management and employees may be deemed to be participants in the
solicitation of proxies in respect of the proposed transaction.
Information about the directors and executive officers of Coherus,
including a description of their direct or indirect interests, by
security holdings or otherwise, is set forth in Coherus’ proxy
statement for its 2023 Annual General Meeting, which was filed with
the SEC on April 17, 2023, the Annual Report on Form 10-K for the
year ended December 31, 2022 filed with the SEC on March 6, 2023,
subsequent Quarterly Reports on Form 10-Q and other documents that
may be filed from time to time with the SEC. Information about the
directors and executive officers of Surface, including a
description of their direct or indirect interests, by security
holdings or otherwise, is set forth in Surface’s Annual Report on
Form 10-K for the year ended December 31, 2022 filed with the SEC
on March 9, 2023 and amended on May 1, 2023, subsequent Quarterly
Reports on Form 10-Q and other documents that may be filed from
time to time with the SEC. Other information regarding the
participants in the proxy solicitations and a description of their
direct and indirect interests, by security holdings or otherwise,
will be contained in the proxy statement/prospectus included in the
Registration Statement on Form S-4 and other relevant materials to
be filed with the SEC regarding the proposed transaction when such
materials become available. Security holders, potential investors
and other readers should read the proxy statement/prospectus,
included in the Registration Statement on Form S-4 carefully when
it becomes available before making any voting or investment
decision. You may obtain free copies of these documents from
Coherus or Surface using the sources indicated above.
Coherus ContactsInvestor
RelationsMarek Ciszewski, SVP Investor Relations IR@coheus.com
Media RelationsJodi Sievers, VP Corporate
Communicationsmedia@coherus.com
Surface Oncology
ContactInvestor RelationsScott Young - VP, Investor
Relations & Corporate Communications
Syoung@surfaceoncology.com
Surface Oncology (NASDAQ:SURF)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Surface Oncology (NASDAQ:SURF)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024